Global /South Korea /Healthcare /Drug Manufacturers - General /260660

Korea Arlico Pharm Co.,Ltd.

260660

• KRX: 260660 • Delayed

3,660KRW 0.5%

2.41 USD

As of 15 June 2026, Korea Arlico Pharm Co.,Ltd. has a market cap of $36.95M USD, ranking #32763 globally and #1962 in South Korea. It ranks #2957 in the Healthcare sector, and #1021 in the Drug Manufacturers - General industry.

Global Rank

32763

Country Rank

1962

Sector Rank

2957

Industry Rank

1021

Key Stats

Market Cap

$36.95MUSD

56.1B KRW

Enterprise Value

$55.43MUSD

84.15B KRW

Revenue (TTM)

$132.54MUSD

201.2B KRW

EBITDA (TTM)

$3.9MUSD

5.92B KRW

Net Income (TTM)

-$398.77KUSD

-605.35M KRW

EBITDA Margin

2.9%

Profit Margin

-0.3%

PS Ratio

0.3

PB Ratio

0.7

EV/EBITDA

14.2

Company Profile

Country (HQ)

South Korea

Sector

Healthcare

Industry

Drug Manufacturers - General

CEO

Hang-Gu Lee open_in_new

Employees

112

Founded

1992

Website

arlico.co.kr open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
0.5%	1.1%	4.3%	-11%	-6.5%	-15%	-14%	-45%	-57%

News

Markets

Exchange	Ticker	Price	Quotes
Korea Exchange (KRX) MIC: XKRX PRIMARY	260660 알리코제약(주) ISIN: KR7260660006 Shares Out.: Shares Outstanding: 15.013M¹ Shares Float: 8.843M² TV: TradingView: KRX: 260660 SA: Stock Analysis: KRX: 260660 YF: Yahoo Finance: 260660.KS GF: Google Finance: KRX: 260660 BA: Barron's: 260660 MS: Morningstar: XKRX: 260660	3,660 KRW	TV: TradingView: KRX: 260660 SA: Stock Analysis: KRX: 260660 YF: Yahoo Finance: 260660.KS GF: Google Finance: KRX: 260660 BA: Barron's: 260660 MS: Morningstar: XKRX: 260660

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About Korea Arlico Pharm Co.,Ltd.

Korea Arlico Pharm Co.,Ltd. engages in the researches and develops, produces, and sells medicines in South Korea. The company provides ETC, OTC, medical device, and other products; and active ingredients. It offers products in the areas of circulatory system, anti-platelet, dementia, muscle relaxants, diabetes, NSAIDS and analgesics, ointment/cream, respiratory system, gastrointestinal, metabolic disease, antihistamines, anti-virus, genitourinary, alopecia, psychoneurotic, CNS, anthelmintics, and hypnotic diseases. Korea Arlico Pharm Co.,Ltd. was founded in 1992 and is headquartered in Seoul, South Korea.

Similar Companies

Industry: Drug Manufacturers - General (South Korea)

Name	Market Cap (USD) diff.	PE	Country
Samsung Epis Holdings Co., Ltd. KRX: 0126Z0	$9.16B 13.91T KRW 25K%	-	South Korea
Sam Chun Dang Pharm. Co., Ltd. KRX: 000250	$6.79B 10.3T KRW 18K%	1958.1	South Korea
SK Biopharmaceuticals Co., Ltd. KRX: 326030	$5.25B 7.97T KRW 14K%	29.9	South Korea
ABL Bio Inc. KRX: 298380	$4.97B 7.55T KRW 13K%	-	South Korea
Yuhan Corp. KRX: 000100	$4.56B 6.92T KRW 12K%	35.9	South Korea
LigaChem Biosciences Inc. KRX: 141080	$4.45B 6.76T KRW 12K%	-	South Korea

Industry: Drug Manufacturers - General (Global)

Name	Market Cap (USD) diff.	PE	Country
Eli Lilly and Co. NYSE: LLY	$761.68B 2M%	38.1	United States
Johnson & Johnson NYSE: JNJ	$547.28B 1M%	26.4	United States
AbbVie Inc. NYSE: ABBV	$360.63B 976K%	97.4	United States
Roche Holding AG SIX: RO	$320.51B 256.25B CHF 867K%	19.9	Switzerland
AstraZeneca PLC LSE: AZN	$288.14B 215.59B GBP 780K%	27.6	United Kingdom
Merck & Co., Inc. NYSE: MRK	$274.03B 741K%	15.1	United States

chevron_leftBack